Acute Leukemia of Ambiguous Lineage — Trials

Acute Leukemia of Ambiguous Lineage — Trials · CancerIndex

Clinical trials

Registered studies

139 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 65
Recruiting: 38
Ph III recruiting: 2
Growth YoY: —
Industry share: 14%
Top sponsor: Fred Hutchinson Cancer Center
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (20)

clinicaltrialsPublishedShowing 1–25 of 25 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06317662	Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	recruiting	Phase 2	153	National Cancer Institute (NCI)NIH	2	Sep 25, 2026	clinicaltrials
NCT04065399	A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation(AUGMENT-101)	recruiting	Phase 1 / Phase 2	447	Syndax PharmaceuticalsINDUSTRY